AKUMS750.00

Akums Drugs and Pharmaceuticals Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersALIVUSAGARWALEYEADVENZYMESAPLLTDAARTIPHARMAARTIDRUGSCORONAHCGMcap ₹11,483 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations4,118.24,359.04,501.6
Other Income52.1128.7132.4
Total Income4,170.34,487.74,634.0
Expenses
+ Cost of Materials Consumed2,253.62,298.72,432.9
+ Purchases of Stock-in-Trade181.5201.0206.4
+ Changes in Inventories-1.613.8-62.3
+ Employee Benefit Expense715.8753.8779.1
+ Finance Costs34.694.195.7
+ Depreciation & Amortisation153.4154.6158.7
+ Other Expenses504.4569.7577.7
Total Expenses3,841.74,085.64,188.3
EBITDA464.5522.0567.7
EBIT311.0367.5409.0
Profit
PBT before Exceptional Items328.6402.1445.7
+ Exceptional Items16.7-20.0-20.0
Pretax Income345.3382.1425.7
+ Current Tax79.789.892.5
+ Deferred Tax-78.335.940.5
Tax Expense1.5125.7133.0
Net Income343.8256.4292.7
+ Net Income — Continuing Ops343.8256.4292.7
+ Other Comprehensive Income-1.10.92.3
Total Comprehensive Income342.7257.3295.0
Net Income to Common338.2255.2291.7
Minority Interest5.61.21.0
Per Share
Basic EPS22.6016.6719.05
Diluted EPS22.6016.6719.05
Other Comprehensive Income — detail
+ Other Comprehensive Income-1.10.92.3
+ Items NOT to be Reclassified to P&L-1.41.3
+ Tax on Items NOT to be Reclassified-0.30.47.1
+ Items to be Reclassified to P&L-0.0
+ Tax on Items to be Reclassified0.00.0-1.1
Comprehensive Income — Owners of Parent337.1256.1294.0
Comprehensive Income — Non-controlling Interests5.61.20.9
Per Share — as-filed variants
Basic EPS — Continuing Operations22.6016.6719.05
Diluted EPS — Continuing Operations22.6016.6719.05
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,684.71,845.51,924.6
Gross Margin %40.9142.3442.75
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)328.6402.1445.7
− Exceptional Items (reconciliation)16.7-20.0-20.0
Net Income Adj (tax-effected)327.2269.8306.5
EPS Adj21.5117.5419.95
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value30,163.932.002.00
Paid Up Equity Capital30.630.630.6
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.